Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))

Emanuel Bührer; Nina Glassee; Michal Kicinski; Oliver J. Kennedy; Christian U. Blank; Georgina V. Long; Victoria G. Atkinson; Stéphane Dalle; Andrew M. Haydon; Andrey Meshcheryakov; Adnan Khattak; Matteo S. Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A. Ascierto; Piotr Rutkowski; Dirk Schadendorf; Marye Boers-Sonderen; Anna Maria Di Giacomo; Alfonsus J.M. van den Eertwegh; Jean Jacques Grob; Ralf Gutzmer; Rahima Jamal; Alexander C.J. van Akkooi; Sara Gandini; Sara Valpione; Stefan Suciu; Caroline Robert; Alexander M.M. Eggermont; Paul Lorigan; Mario Mandala

doi:10.1016/j.ejcskn.2026.101140

Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))

Emanuel Bührer
, Nina Glassee
, Michal Kicinski
, Oliver J. Kennedy
, Christian U. Blank
, Georgina V. Long
, Victoria G. Atkinson
, Stéphane Dalle
, Andrew M. Haydon
, Andrey Meshcheryakov
, Adnan Khattak
, Matteo S. Carlino
, Shahneen Sandhu
, James Larkin
, Susana Puig
, Paolo A. Ascierto
, Piotr Rutkowski
, Dirk Schadendorf
, Marye Boers-Sonderen
, Anna Maria Di Giacomo

Alfonsus J.M. van den Eertwegh, Jean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Sara Gandini, Sara Valpione, Stefan Suciu, Caroline Robert, Alexander M.M. Eggermont, Paul Lorigan, Mario Mandala

Research related

Research output: Contribution to journal › Comment/debate

Abstract

The publisher regrets the omission of the editor is an author declaration: The authors Susanna Puig and Paul Lorigan are Editors of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article.

Original language	English
Article number	101140
Journal	EJC Skin Cancer
DOIs	https://doi.org/10.1016/j.ejcskn.2026.101140
Publication status	Accepted/In press - 2026

Access to Document

10.1016/j.ejcskn.2026.101140

Fingerprint

Dive into the research topics of 'Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))'. Together they form a unique fingerprint.

Cite this

Bührer, E., Glassee, N., Kicinski, M., Kennedy, O. J., Blank, C. U., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Boers-Sonderen, M., ... Mandala, M. (Accepted/In press). Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727)). EJC Skin Cancer, Article 101140. https://doi.org/10.1016/j.ejcskn.2026.101140

Bührer, Emanuel ; Glassee, Nina ; Kicinski, Michal et al. / Erratum to : “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727)). In: EJC Skin Cancer. 2026.

@article{52e05250ceb2481486ec2eca20eb564e,

title = "Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))",

abstract = "The publisher regrets the omission of the editor is an author declaration: The authors Susanna Puig and Paul Lorigan are Editors of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article.",

author = "Emanuel B{\"u}hrer and Nina Glassee and Michal Kicinski and Kennedy, \{Oliver J.\} and Blank, \{Christian U.\} and Long, \{Georgina V.\} and Atkinson, \{Victoria G.\} and St{\'e}phane Dalle and Haydon, \{Andrew M.\} and Andrey Meshcheryakov and Adnan Khattak and Carlino, \{Matteo S.\} and Shahneen Sandhu and James Larkin and Susana Puig and Ascierto, \{Paolo A.\} and Piotr Rutkowski and Dirk Schadendorf and Marye Boers-Sonderen and \{Di Giacomo\}, \{Anna Maria\} and \{van den Eertwegh\}, \{Alfonsus J.M.\} and Grob, \{Jean Jacques\} and Ralf Gutzmer and Rahima Jamal and \{van Akkooi\}, \{Alexander C.J.\} and Sara Gandini and Sara Valpione and Stefan Suciu and Caroline Robert and Eggermont, \{Alexander M.M.\} and Paul Lorigan and Mario Mandala",

note = "Publisher Copyright: {\textcopyright} 2026 The Authors",

year = "2026",

doi = "10.1016/j.ejcskn.2026.101140",

language = "English",

journal = "EJC Skin Cancer",

issn = "2772-6118",

publisher = "Elsevier BV",

}

Bührer, E, Glassee, N, Kicinski, M, Kennedy, OJ, Blank, CU, Long, GV, Atkinson, VG, Dalle, S, Haydon, AM, Meshcheryakov, A, Khattak, A, Carlino, MS, Sandhu, S, Larkin, J, Puig, S, Ascierto, PA, Rutkowski, P, Schadendorf, D, Boers-Sonderen, M, Di Giacomo, AM, van den Eertwegh, AJM, Grob, JJ, Gutzmer, R, Jamal, R, van Akkooi, ACJ, Gandini, S, Valpione, S, Suciu, S, Robert, C, Eggermont, AMM, Lorigan, P & Mandala, M 2026, 'Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))', EJC Skin Cancer. https://doi.org/10.1016/j.ejcskn.2026.101140

Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727)). / Bührer, Emanuel; Glassee, Nina; Kicinski, Michal et al.
In: EJC Skin Cancer, 2026.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Erratum to

T2 - “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727))

AU - Bührer, Emanuel

AU - Glassee, Nina

AU - Kicinski, Michal

AU - Kennedy, Oliver J.

AU - Blank, Christian U.

AU - Long, Georgina V.

AU - Atkinson, Victoria G.

AU - Dalle, Stéphane

AU - Haydon, Andrew M.

AU - Meshcheryakov, Andrey

AU - Khattak, Adnan

AU - Carlino, Matteo S.

AU - Sandhu, Shahneen

AU - Larkin, James

AU - Puig, Susana

AU - Ascierto, Paolo A.

AU - Rutkowski, Piotr

AU - Schadendorf, Dirk

AU - Boers-Sonderen, Marye

AU - Di Giacomo, Anna Maria

AU - van den Eertwegh, Alfonsus J.M.

AU - Grob, Jean Jacques

AU - Gutzmer, Ralf

AU - Jamal, Rahima

AU - van Akkooi, Alexander C.J.

AU - Gandini, Sara

AU - Valpione, Sara

AU - Suciu, Stefan

AU - Robert, Caroline

AU - Eggermont, Alexander M.M.

AU - Lorigan, Paul

AU - Mandala, Mario

PY - 2026

Y1 - 2026

N2 - The publisher regrets the omission of the editor is an author declaration: The authors Susanna Puig and Paul Lorigan are Editors of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article.

AB - The publisher regrets the omission of the editor is an author declaration: The authors Susanna Puig and Paul Lorigan are Editors of EJC Skin Cancer and were not involved in the editorial review or the decision to publish this article.

UR - https://www.scopus.com/pages/publications/105035788304

U2 - 10.1016/j.ejcskn.2026.101140

DO - 10.1016/j.ejcskn.2026.101140

M3 - Comment/debate

AN - SCOPUS:105035788304

SN - 2772-6118

JO - EJC Skin Cancer

JF - EJC Skin Cancer

M1 - 101140

ER -

Bührer E, Glassee N, Kicinski M, Kennedy OJ, Blank CU, Long GV et al. Erratum to: “Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma” [EJC Skin Cancer 3 (2025) 100727] (EJC Skin Cancer (2025) 3, (S2772611825004483), (10.1016/j.ejcskn.2025.100727)). EJC Skin Cancer. 2026;101140. doi: 10.1016/j.ejcskn.2026.101140